REV-ERB agonist raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-03-03 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory agencies have not approved SR9009 for human therapeutic use. It is typically sold as a research chemical with labels stating that it is not for human consumption. The World Anti-Doping Agency prohibits the substance in sport, generally under the category of non-approved substances. Customs and national laws may restrict importation, sale, or possession. Product quality and legal status can vary by country and vendor, and therapeutic claims are not permitted in regulated advertising because the compound lacks approval.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Identity and purity testing for SR9009 commonly uses liquid chromatography coupled with tandem mass spectrometry. This method separates the compound from matrix components and detects it by mass-to-charge transitions, providing sensitive and specific confirmation. Nuclear magnetic resonance spectroscopy can support structural identification, while high-performance liquid chromatography with ultraviolet detection may estimate purity. Because online products labeled as SR9009 may contain other substances or no active compound at all, independent verification is important in research settings. Certificates of analysis are useful but not a substitute for in-house testing.
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
== Clinical significance == Mutations in the POMC gene have been associated with early-onset obesity, adrenal insufficiency, and red hair pigmentation. In cases of primary adrenal insufficiency, decreased cortisol production leads to compensatory overproduction of pituitary ACTH through feedback mechanisms. Because ACTH is co-produced with α-MSH and γ-MSH from POMC, this overproduction can result in hyperpigmentation. A specific genetic polymorphism in the POMC gene is associated with elevated fasting insulin levels, but only in obese individuals. The melanocortin signaling pathway may influence glucose metabolism in the context of obesity, indicating a possible gene–environment interaction. Thus, POMC variants may contribute to the development of polygenic obesity and help explain the connection between obesity and type 2 diabetes. Increased circulating levels of POMC have also been observed in patients with sepsis. While the clinical implications of this finding are still under investigation, animal studies have shown that infusion of hydrocortisone in septic mice suppresses ACTH (a downstream product of POMC) without reducing POMC levels themselves.
== Entactogens == Entactogens are a class of psychoactive drugs that produce distinctive emotional and social effects similar to those of MDMA. Users of entactogens say the drugs often produce feelings of empathy, love, and emotional closeness to others.
== Ductal cell physiology == While ductal cells are a minor type of cell in the adult pancreas, they have a critical function besides making the network that transfers enzymes from acini to the digestive tract. The primary function of pancreas ductal cells is to secrete a bicarbonate-rich, isotonic fluid. This fluid washes away the inactive form of digestive enzymes in the ductal system, neutralizes stomach acidity and mucins, and creates a pH environment necessary for the pancreas's normal function. Multiple factors affect the rate of bicarbonate secretion: species, cell location in the ductal system, secretory rate, etc. When stimulated, bicarbonate levels can get to 140mM. Due to this, there is a contrast in concentration between the outside and inside environment of ductal cells. The channels and ion transporters on ductal cells vary on the luminal and basolateral membrane, meaning there is functional polarization of the ductal cell. The largest network branches in this system contain goblet cells that interact with ductal cells, making up about 2% of this structure—these cells aid mucin assembly. Furthermore, unlike other exocrine glands, the pancreas does not have myoepithelial cells around the ducts. Ductal cells have a single cilium that is made up of nine peripheral doublets but does not have a central microtubule. This cilium is considered vital for perceiving flow in ducts.
== Preparation == Imidazole was first reported in 1858 by the German chemist Heinrich Debus, although various imidazole derivatives had been discovered as early as the 1840s. It was shown that glyoxal, formaldehyde, and ammonia condense to form imidazole (glyoxaline, as it was originally named). This synthesis, while producing relatively low yields, is still used for generating C-substituted imidazoles.
== History == Medtronic replaced the Paradigm insulin pump with its new pump platform, the 640G, internationally in 2015. Its successive pumps have used the same form factor. In the United States, the 670G was released in 2017. It used an algorithm called SmartGuard to adjust the basal insulin rate based on readings from the CGM (continuous glucose monitor). A more advanced SmartGuard algorithm was released in 2020 (2023 in the United States) as part of the 780G. It can deliver automated boluses and has an optional glucose target of 100 mg/dl. The 670G used Medtronic's own proprietary algorithm. For the 780G, the SmartGuard algorithm was adapted from an algorithm licensed by Medtronic in 2015 from medical technology company DreaMed. DreaMed, based at the Schneider Children's Medical Center of Israel in Tel Aviv, created the algorithm in the late 2000s. At first called MD-Logic Artificial Pancreas, then GlucoSitter, it used machine learning to increase the patient's time in the 80–120 mg/dl range. DreaMed's algorithm performed well in clinical trials as of 2011. Initially, the pump was compatible only with MiniMed's own CGMs, the Guardian 3 and Guardian 4. In 2025, MiniMed introduced two new CGMs for the 780G, the Simplera Sync and the Instinct, made by Abbott Laboratories.
Sources: en.wikipedia.org
Fully annexed localities (Auteuil, Batignolles-Monceau, Belleville, Bercy, Charonne, Grenelle, La Chapelle, La Villette, Montmartre, Passy, and Vaugirard): Everything disappeared along with the registers of the Parisian arrondissements—both originals and duplicates. Partially annexed localities (Aubervilliers, Bagnolet, Clichy, Gentilly, Ivry, Montrouge, Neuilly, Pantin, Le Pré-Saint-Gervais, Saint-Mandé, Saint-Ouen, and Vanves) or non-annexed areas (the rest of what is today known as the Petite Couronne): The originals, having been preserved locally, are still accessible in municipal archives unless transferred to the Departmental Archives of Hauts-de-Seine, Seine-Saint-Denis, or Val-de-Marne. The duplicates, however, were destroyed, except for the decennial tables covering 1793–1859.
In this mechanism, the intermediate forms the product by adding another proton to C2. It was expected that solvent protons would contribute to forming the product from the enediol intermediate of the proton-transfer mechanism and when such contributions were not observed in tritiated water, 3H1O, the hydride-transfer mechanism was favored. However, an alternate hypothesis — that the enzyme active site was deeply buried away from water — could not be ruled out and ultimately proved to be correct. The first indications came when ever-increasing temperatures showed ever-increasing incorporation of tritium, which is consistent with proton transfer and unexpected by hydride transfer. The clinching evidence can with studies of the hydrogen-deuterium isotope effect on substrates fluorinated on the methyl group and deuterated on the aldehyde. The fluoride is a good leaving group; the hydride-transfer mechanism predicts less fluoride ion elimination with the deuterated sample, whereas the proton-transfer mechanism predicts more. Experiments on three types of glyoxalase I (yeast, rat and mouse forms) supported the proton-transfer mechanism in every case. This mechanism was finally observed in crystal structures of glyoxalase I.
Nausea and vomiting are two of the most feared cancer treatment-related side-effects for people with cancer and their families. In 1983, Coates et al. found that people receiving chemotherapy ranked nausea and vomiting as the first and second most severe side-effects, respectively. Up to 20% of people receiving highly emetogenic agents in this era postponed, or even refused potentially curative treatments. Chemotherapy-induced nausea and vomiting (CINV) are common with many treatments and some forms of cancer. Since the 1990s, several novel classes of antiemetics have been developed and commercialized, becoming a nearly universal standard in chemotherapy regimens, and helping to successfully manage these symptoms in many people. Effective mediation of these unpleasant and sometimes debilitating symptoms results in increased quality of life for the recipient and more efficient treatment cycles, as patients are less likely to avoid or refuse treatment.
MCl2 + 2 NaC5H5 → (C5H5)2M + 2 NaCl (M = V, Cr, Mn, Fe, Co; solvent = THF, DME, NH3) CrCl3 + 3 NaC5H5 → [(C5H5)2Cr] + 1⁄2 "C10H10" + 3 NaCl NaCp acts as a reducing agent and a ligand in this reaction.
== Second island chain == The second island chain, also called the "second island cloud" by Earl Hancock Ellis, has two different interpretations, but the version most commonly used refers to the island chain which is formed by Japan's Bonin Islands and Volcano Islands, in addition to the Mariana Islands (most notably Guam, an unincorporated American overseas territory with a heavily fortified military base), western Caroline Islands (Yap and Palau), and extends to Western New Guinea. The chain serves as the eastern maritime boundary of the Philippine Sea. As it is located within the middle portion of the West Pacific, it acts as a second strategic defense line for the United States.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.